Gsk2118436a

Manufactured by Selleck Chemicals

Sourced in United States

GSK2118436A is a laboratory compound used for research purposes. It is a selective inhibitor of the BRAF kinase enzyme. The core function of GSK2118436A is to inhibit BRAF kinase activity in vitro and in cellular assays.

Automatically generated - may contain errors

Lab products found in correlation

Lgx818, by MedChemExpress (2 mentions) Plx4032, by MedChemExpress (2 mentions) Plx8394, by MedChemExpress (2 mentions) Az628, by Selleck Chemicals (1 mentions) Ly3009120, by Selleck Chemicals (1 mentions) Tak 632, by Selleck Chemicals (1 mentions) Gdc 0879, by Selleck Chemicals (1 mentions) Azd6244, by Selleck Chemicals (1 mentions) Lm609, by Merck Group (1 mentions) Sb 505124, by Merck Group (1 mentions) Dabrafenib, by Selleck Chemicals (1 mentions) E 100, by Alomone (1 mentions)

3 protocols using gsk2118436a

Comparative Analysis of BRAF and MEK Inhibitors

Check if the same lab product or an alternative is used in the 5 most similar protocols

BRAFi used are as follows: PLX4032 (vemurafenib; MedChemExpress, #HY-12057), LGX818 (encorafenib; MedChemExpress, #HY-15605), GSK2118436A (dabrafenib; Selleckchem, #S2807), PLX8394 (MedChemExpress, #HY-18972), AZ628 (Selleckchem, #S2746), GDC0879 (Selleckchem, #S1104), LY3009120 (Selleckchem, #S7842), and TAK632 (Selleckchem, #S7291). MEKi used are as follows: AZD6244 (selumetinib; Selleckchem, #S1008), BAY86-9766 (refametinib; MedChemExpress, #HY-102156), and benzyl-coelenterazine (NanoLight, #301).

Röck R., Mayrhofer J.E., Torres-Quesada O., Enzler F., Raffeiner A., Raffeiner P., Feichtner A., Huber R.G., Koide S., Taylor S.S., Troppmair J, & Stefan E. (2019). BRAF inhibitors promote intermediate BRAF(V600E) conformations and binary interactions with activated RAS. Science Advances, 5(8), eaav8463.

+ Open protocol

+ Expand

Integrin αvβ3 Inhibition in BRAF Signaling

Check if the same lab product or an alternative is used in the 5 most similar protocols

CsA was purchased from Santa Cruz Biotechnology, the TGFβ receptor I (ALK5) inhibitor SB505124 from Sigma-Aldrich, and the BRAF inhibitor Dabrafenib (GSK2118436A) from Selleckchem (Houston, TX, USA). The function-blocking antibody to integrin αvβ3 (LM609) was acquired from Merck Millipore.

Eriksson J., Le Joncour V., Nummela P., Jahkola T., Virolainen S., Laakkonen P., Saksela O, & Hölttä E. (2016). Gene expression analyses of primary melanomas reveal CTHRC1 as an important player in melanoma progression. Oncotarget, 7(12), 15065-15092.

+ Open protocol

+ Expand

Evaluating BRAF inhibitor combinations

Check if the same lab product or an alternative is used in the 5 most similar protocols

The reagents used included PLX4032 (vemurafenib; MedChemExpress, HY-12057), LGX818 (encorafenib; MedChemExpress, HY-15605), GSK2118436A (dabrafenib; Selleckchem, S2807), PLX8394 (MedChemExpress, HY-18972), Benzyl-coelenterazine (Nanolight, 301), and human EGF (Alomone Labs, E-100).

Mayrhofer J.E., Enzler F., Feichtner A., Röck R., Fleischmann J., Raffeiner A., Tschaikner P., Ogris E., Huber R.G., Hartl M., Schneider R., Troppmair J., Torres-Quesada O, & Stefan E. (2020). Mutation-oriented profiling of autoinhibitory kinase conformations predicts RAF inhibitor efficacies. Proceedings of the National Academy of Sciences of the United States of America, 117(49), 31105-31113.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!